Dendritic cells, headhunters for anti-tumor CD8+ T cells in triple-negative breast cancer

Carlos Luri-Rey; Almudena Manzanal; Beatrice Pinci; Alvaro Teijeira

doi:10.1016/j.medj.2023.05.004

Dendritic cells, headhunters for anti-tumor CD8⁺ T cells in triple-negative breast cancer

Med. 2023 Jun 9;4(6):341-343. doi: 10.1016/j.medj.2023.05.004.

Authors

Carlos Luri-Rey¹, Almudena Manzanal¹, Beatrice Pinci¹, Alvaro Teijeira²

Affiliations

¹ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
² Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: ateijeiras@unav.es.

PMID: 37301193
DOI: 10.1016/j.medj.2023.05.004

Abstract

How do we identify patients most likely to benefit from immune checkpoint blockade therapies? This month in Med, Wu and colleagues¹ identify that CCL19⁺ mature dendritic cells correlated with responses to anti-PD-(L)1 immunotherapy in triple-negative breast cancer patients, suggesting the use of CCL19 as a biomarker to predict patient outcomes.

MeSH terms

CD8-Positive T-Lymphocytes*
Dendritic Cells
Humans
Triple Negative Breast Neoplasms* / drug therapy